Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
M.H. Otten(Erasmus University Rotterdam), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), R. ten Cate(Leiden University), Koert M. Dolman(Reade), Y. Koopman-Keemink(Juliana Kinderziekenhuis), Flora B. de Waard‐van der Spek(Erasmus MC), Wineke Armbrust, Simone Gorter(University Medical Center Groningen), Marion A. J. van Rossum(Reade), Esther P A H Hoppenreijs(Radboud University Nijmegen), NM Wulffraat(Wilhelmina Children's Hospital), Marinka Twilt(University of Calgary)
Cited by 35
Related Papers
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
Autologous haematopoietic stem cell transplants for autoimmune disease – feasibility and transplant-related mortality
|Bone Marrow Transplantation|1999|169
Predictors of health‐related quality of life in children and adolescents with juvenile idiopathic arthritis: Results from a web‐based survey
|Arthritis Care & Research|2012|155